FIRST-QUARTER EARNINGS PREVIEW: Amgen, Biogen, Celgene
This article was originally published in Scrip
Executive Summary
Amgen’s shares have been on a tear, rising more than a third in the past three months. Bad news for a competitor in the dialysis market and a surprise upside for an experimental melanoma drug helped lift the stock. (scripintelligence.com March 20)